Latest Breaking News On - Curanto pharma - Page 1 : comparemela.com

This is the first vaccine to test immunology in children as young as three years old. The most reported side effect was injection-site pain. A new study has found that two doses of the CoronaVac vaccine were safe and well-tolerated in children and adolescents aged three to 17 years old. The research published in The Lancet is the first to report on the immunogenicity and safety of a Covid-19 candidate vaccine in children as young as three years. CoronaVac was on Saturday approved for use in South Africa - with conditions - by the South African Health Products Regulatory (Sahpra). The regulator, however, only approved the vaccine for adults aged between 18 and 59. The authorisation was based on the safety, quality and efficacy data submitted by Curanto Pharma to Sahpra between 22 March and 22 June, according to a News24 report.

South africaAfrican health products regulatory sahpraSouth african health products regulatoryCuranto pharmaChinese sinovacProf bin cao